9/10
08:00 am
mbrx
Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Medium
Report
Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.